

KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH



(A unit of Kovai Medical Centre & Hospital) Coimbatore-641014, Tamil Nadu

DEPARTMENT OF PHARMACOLOGY


NEW DRUG UPDATE

Series No: 69, MARCH, 2025

S.N O	DRUG & APPROVAL DATE	MECHANISM	INDICATION	DOSAGE FORMS
1.	Revakinagene taroretcel-lwey	Recombinant ciliary neurotrophic factor (rhCNTF), a potent neuroprotective protein that promotes the survival and maintenance of photoreceptors.	Idiopathic macular telangiectasia type 2	Intravitreal Implant
2.	Omalizumab-igec 7/3/25	Anti-IgE antibody	Asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and urticaria.	Subcutaneous Injection
3.	Losartan potassium 13/3/25	Angiotensin II receptor blocker	Hypertension and diabetic nephropathy.	Oral Suspension
4.	Gallium Ga 68 Gozetotide 20/3/25	Radioactive diagnostic agent	Positron Emission Tomography Imaging	Intravenous bolus injection.
5.	Denosumab-bnht 25/3/25	RANK ligand (RANKL) inhibitor	Osteolytic Bone Lesions of Multiple Myeloma, Osteolytic Bone Metastases of Solid Tumors, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy, Osteoporosis	Subcutaneous Injection



KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH





6.	Gepotidacin 25/3/25	Bacterial type II topoisomerase inhibitor	Uncomplicated urinary tract infections.	Tablets
7.	Diazoxide choline 26/3/25	Activating ATP-sensitive potassium channels (KATP channels)	Hyperphagia in patients with Prader-Willi syndrome	Extended-Rele ase Tablets
8.	Fitusiran 28/3/25	Antithrombin-direct ed- small interfering RNA (siRNA)	Hemophilia A or B with or without factor VIII or IX inhibitors.	Subcutaneous Injection

Contact Details:

Email your suggestions to: hodpharmacology@kmchihsr.edu.in

Website: http://www.kmchihsr.edu.in